Ocugen, Inc. (OCGN) Stock Price, News & Quote

OCGN Stock Price

For anyone interested in the latest updates and insights related to OCGN stock price and news, FintechZoom provides a comprehensive platform that offers real-time information and analysis.

Stock Overview

This “Stock Overview” table offers a snapshot of a company’s performance.

Price: This is the current market value, telling you how much one share costs.

Change: This shows how much the price moved compared to yesterday, green for up, red for down.

Volume: This tells you how many shares were traded, suggesting activity and investor interest.

High/Low/Open: These show the price range during the day and where it started (open) and finished (close).

Previous Close: This is yesterday’s closing price, providing context for today’s change.

52-Week High/Low: These tell you the stock’s peak and valley over the past year, helping assess current price relative to its broader trend.

OCGN Stock News

OCGN Stock Prices Change

History of Ocugen, Inc.

Ocugen, Inc. is a relatively young player in the biotech scene, but its journey has been marked by significant milestones and ambitious goals. Here’s a glimpse into the company’s history:

Early Beginnings (2013-2019):

2013: Founded by Shankar Musunuri, a seasoned biotech veteran, under the name Histogenics Corporation.
Focus: Initially focused on developing regenerative therapies for orthopedic and dental applications.
2017: Pivots towards ophthalmology, recognizing the unmet needs in treating eye diseases.

Shifting Gears and Building Momentum (2020-present):

2020: Acquires Ocugen, Inc., a company specializing in gene and cell therapies for eye diseases.
2021: Officially adopts the Ocugen, Inc. name and embarks on an ambitious pipeline expansion.
Key Acquisitions:
- Collaboration with Bharat Biotech: Secures rights to manufacture and commercialize Covaxin, a COVID-19 vaccine, in the US and Canada.
- GeneSight: Acquires gene therapy platform with potential for treating multiple retinal diseases.
2023:
- Phase 3 Trial Progress: OCU300, a gene therapy for wet age-related macular degeneration (AMD), receives Orphan Drug Designation from the FDA.
- Financial Growth: Beats earnings expectations in Q3, showcasing promising financial trajectory.

Future Outlook:

Ocugen is poised for continued growth, with its focus on innovative gene and cell therapies holding immense potential. The company’s pipeline boasts promising candidates for treating various eye diseases, along with the Covaxin partnership adding another dimension to its portfolio.

Challenges and Opportunities:

The competitive landscape in ophthalmology is fierce, requiring Ocugen to excel in clinical development and regulatory approvals.
Successfully navigating the manufacturing and commercialization of Covaxin will be crucial for establishing Ocugen’s presence in the broader vaccine market.

Overall, Ocugen’s journey is a testament to its commitment to developing transformative therapies for patients with eye diseases. With a robust pipeline, strategic partnerships, and a passionate team, Ocugen is well-positioned to leave its mark on the world of ophthalmology.

Officers and Directors

Buy OCGN Stock

See OCGN stock price on stock market and Buy/Sell OCGN with any amount of money. Discuss news and analysts’ price predictions with the investor community.

Invest Now